Skip to content

Harm-reduction information only — not medical advice. In crisis or experiencing adverse effects, contact a healthcare professional or your local emergency services immediately.

AnabolicPlotter logo AnabolicPlotter
Search (no-JS fallback)
Peptides Muscle BuildingAnti-Aging & Longevity Preclinical (animal) data

CJC-1295 without DAC (Modified GRF 1-29)

Mod GRF 1-29 · CJC-1295 NO DAC · CJC no DAC

29 min
Half-life
100–500 mcg
Typical dose
8–12 weeks
Cycle length

Short-acting GHRH analog (~30 min half-life) usually paired with a GHRP for pulsatile GH release.

Key takeaways

  • Short-acting GHRH analog (Mod GRF 1-29) with a ~30-minute half-life.
  • Produces physiologic GH pulses rather than the DAC version's sustained elevation.
  • Usually stacked 1:1 with a GHRP (ipamorelin, GHRP-2) for a larger pulse.
  • Direct human trials are lacking; dosing conventions are community-derived.

Overview

What it is

CJC-1295 without DAC, better known as modified GRF 1-29, is a short-acting GHRH analog with four amino acid substitutions that resist enzymatic breakdown. It acts on pituitary GHRH receptors to trigger growth hormone release in a pulsatile, physiologic pattern.

Pharmacokinetics

Without the albumin-binding DAC, the half-life drops back to roughly 30 minutes with around 60% subcutaneous bioavailability. That short window is why it is almost always paired with a GHRP like ipamorelin: the two classes amplify GH release through separate receptors.

What the evidence says

Direct human data on this modified analog is thin. The parent GRF(1-29) sequence (sermorelin) has real clinical history, but the modified peptide's dosing conventions are community-derived, and it is not an approved medication.

Reported dosing protocols

Protocols reported in research literature and clinic/community use — informational context, not a dosing recommendation.

Use case Dose Route Frequency Duration
GH pulse (community) 100–300 mcg SubQ 1–3× daily, fasted or pre-bed 8–12 weeks

Pharmacokinetic summary

Model tier
Simple (t½ + F, Tmax estimated)
Half-life
29 min
Bioavailability
60%
Typical dose
0.1–0.5 mg

Frequently asked questions

Why combine CJC-1295 no DAC with a GHRP?

GHRH analogs and GHRPs hit different receptors (GHRH-R vs the ghrelin receptor), and the combination is synergistic: the GH pulse from both together exceeds either alone. That is why blends like CJC/ipamorelin are standard in research use.

Why dose it fasted or before bed?

Food and elevated blood sugar blunt GH release, so fasted dosing gives a cleaner pulse. Pre-bed dosing aims to amplify the large natural nocturnal GH pulse. The logic is physiological, though comparative human data is lacking.

Mod GRF vs CJC-1295 with DAC — how do they differ?

Same base peptide, different duration. Without DAC the half-life is ~30 minutes and dosing is daily, often multiple times. With DAC, one injection gives about a week of sustained elevation. Vendor labeling mix-ups between the two are a known community complaint.

References

  • Estimated — Without DAC the half-life is ~30 minutes; typically combined with a GHRP.

Related compounds

Protocols featuring CJC-1295 without DAC (Modified GRF 1-29)

Comments

Loading comments…